Key result
PARP7 drives angiotensin II-induced vascular remodeling by inhibiting GPX4 in vascular smooth muscle cells.
Its licence doesn't allow us to show a copy here.
Reveals that PARP7 drives angiotensin II-induced vascular remodeling via GPX4 ADP-ribosylation in vascular smooth muscle cells, indicating a potential target for cardiovascular therapy.
Pathological vascular remodeling is driven by metabolic imbalance in vascular smooth muscle cells (VSMCs). NAD
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question. PARP7 drives angiotensin II-induced vascular remodeling through ADP-ribosylation and the inhibition of GPX4 in vascular smooth muscle cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: